EFPIA seeks "soft law approach" rather than wholesale revision of EU pricing legislation
This article was originally published in SRA
Executive Summary
Reopening the so-called "Transparency Directive" on the pricing and reimbursement of medicines must not compromise the confidentiality of pricing arrangements between pharmaceutical companies and payers, says Richard Bergström, director general of the European Federation of the Pharmaceutical Industries and Associations (EFPIA)1. Revealing details of such agreements would prevent differential pricing, he said. Mr Bergström's comments came as EFPIA responded to the European Commission's consultation on the possible review of the Transparency Directive (89/105/EEC).